Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Frequently Asked Questions on PAH

James C. Coons, PharmD, FCCP, FACC, BCCP

University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
UPMC Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania

James C. Coons, PharmD, FCCP, BCCP, has conducted contracted research for Pfizer and United Therapeutics; received consulting fees from Alnylam and Bristol Myers Squibb.

View ClinicalThoughts from this Author

Martha Kingman, DNP, FNP-C

Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Martha Kingman, DNP, FNP-C, has conducted contracted research for and received consulting fees from Acceleron, Actelion, and United Therapeutics; received consulting fees from Altavant, Caremark, CiVi Biopharma, Gossamer Bio, and Liquidia; conducted contracted research for Reata and Sonavie.

View ClinicalThoughts from this Author

Vallerie V. McLaughlin, MD

Kim A. Eagle Endowed Professor of Cardiovascular Medicine
Associate Chief Clinic Officer
Cardiovascular Medicine, Internal Medicine
University of Michigan
Ann Arbor, Michigan

Vallerie McLaughlin, MD, has received consulting fees from Actelion/J&J, Bayer, and United Therapeutics.

View ClinicalThoughts from this Author

Released: March 30, 2021

In this commentary, James C. Coons, PharmD, FCCP, BCCP; Martha Kingman, DNP, FNP-C; and Vallerie McLaughlin, MD, answer questions from a ProCE webinar on the management of pulmonary arterial hypertension (PAH). Slides from the webinar are also available for self-study or to use in your noncommercial presentations.

What is the average life expectancy for patients with PAH?

Martha Kingman, DNP, FNP-C:
In the 1980s, when there were no FDA-approved therapies, the National Institutes of Health collected survival data: average survival was 2.8 years. Today, we have 14 FDA-approved therapies for PAH and the average survival has improved to 7 years. This is still an unacceptable life expectancy and we hope to continue to see this improve as more therapies come to market.

What is the role of generic medications, in particular parenteral generics, in the treatment of PAH? Why are some PAH centers hesitant to prescribe generics?

Vallerie McLaughlin, MD:
This is a very difficult question. I think provider comfort with equivalency and production are the 2 biggest concernswarranted or notthat contribute to any hesitancy to use generics in PAH.

PAH medications have a narrow therapeutic range, so we want to know what we’re getting and make sure that any generic is bioequivalent. I think that physicians, providers, and nurse practitioners have a comfort level with what they’re used to usingthey want to be sure the patient is on what they’re supposed to be on.

There can also be worries about production. I remember years ago, a generic form of epoprostenol had a production problem forcing the plant to shut down. Everybody who was receiving the generic drug had to be transitioned back to the branded drug, which was very difficult. We were worried about interruptions in therapy.

James C. Coons, PharmD, FCCP, BCCP:
I think that’s a great point. We’ve been faced with the question of whether to use generic PAH drugs at our program, too. In some cases, we have moved to the use of generics, generally with had pretty good success.

The FDA’s approach is to look at bioequivalence, so an agent has to meet a certain range of parameters to be approved as a generic. But for patients with PAH, who can be tenuous, we have to be mindful of potential small differences making a potential big difference.

Martha Kingman, DNP, FNP-C:
We have a handful of patients who are receiving generic IV therapy now. We carefully selected them, including patients who were very stable, not on high doses, and have done well. But we certainly do have a concern. It’s not something that we do lightly, and we also worry about potential supply chain issues in the future.

What about oxygen therapy for patients with PAH?

Martha Kingman, DNP, FNP-C:
Oxygen therapy is very important in patients who are hypoxemic. Generally, patients with idiopathic PAH do not require oxygen unless they are in very advanced stages of disease. We do see hypoxemia in associated conditions, such as congenital heart disease with right to left shunting and in patients with group 3 PH who are hypoxic from their lung disease.

When patients are hypoxic, whatever the reason, we work diligently to correct this with rest, exercise, and sleep. In the office, we assess resting saturation, and from the 6-minute walk test, we determine the need for oxygen with exertion. We perform an overnight oximetry and sometimes a formal sleep study to assess for nocturnal hypoxia. This is critical because hypoxia causes vasoconstriction of the pulmonary arteries, which can increase the pulmonary pressures.

What is the role of inhaled prostacyclins for PAH, particularly for those formulations that may be used acutely in the hospital?

James C. Coons, PharmD, FCCP, BCCP:
There are 2 FDA-approved inhaled prostacyclins for PAH: iloprost and treprostinil. Any other inhaled prostacyclin, including epoprostenol, which is typically compounded in the hospital setting, is off label for PAH.

If inhaled epoprostenol is used, it may be for indications such as prevention or management of right ventricular dysfunction in the perioperative or postoperative cardiothoracic surgical setting. But inhaled epoprostenol has not been adequately studied for PAH and is not formulated in a way that would be conducive to outpatient administration. Therefore, it would not be useful for patients with PAH.

Share Your Thoughts
What do you feel are the most challenging interprofessional considerations in the management of PAH? Join the conversation by posting in the comments section.

Join the Conversation

Provided by ProCE, LLC, a Clinical Education Alliance Company

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings